Direct Healthcare Professional Communication: 5-Fluorouracil (i.v.), Capecitabine and Tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe and fatal toxicity

This letter to HCPs brings attention the fact that patients with partial or complete dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe and fatal toxicity during treatment with fluoropyrimidines (5-FU, capecitabine, tegafur).

Source:

electronic Medicines compendium